{"filing":{"accession_number":"0001193125-26-342343","cik":"0001572616","ticker":"GUTS","company_name":"FRACTYL HEALTH, INC.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"guts-20260810.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1572616/000119312526342343/guts-20260810.htm"},"events":[{"id":26523,"run_id":24109,"accession_number":"0001193125-26-342343","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release disclosing Fractyl Health's second quarter 2026 financial results, including R\u0026D expenses ($13.8M), SG\u0026A expenses ($5.3M), net loss ($25.5M), adjusted EBITDA (negative $16.3M), and cash position ($47.1M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial metrics and material clinical/business updates regarding the company's Revita and Rejuva programs.","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27677,"accession_number":"0001193125-26-342343","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Fractyl Health's second quarter 2026 financial results, including R\u0026D expenses ($13.8M), SG\u0026A expenses ($5.3M), net loss ($25.5M), adjusted EBITDA (negative $16.3M), and cash position ($47.1M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial metrics and material clinical/business updates regarding the company's Revita and Rejuva programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:08:50.653520+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27677,"accession_number":"0001193125-26-342343","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release disclosing Fractyl Health's second quarter 2026 financial results, including R\u0026D expenses ($13.8M), SG\u0026A expenses ($5.3M), net loss ($25.5M), adjusted EBITDA (negative $16.3M), and cash position ($47.1M). The press release is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings announcements. The disclosure includes both financial metrics and material clinical/business updates regarding the company's Revita and Rejuva programs.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:08:50.653520+00:00","company_name":"FRACTYL HEALTH, INC.","ticker":"GUTS","filing_date":"2026-08-10"}]}